Skip to main content
. 2022 Aug 18;70(34):10521–10531. doi: 10.1021/acs.jafc.2c04518

Table 3. RSV and Related Metabolites Determined by GC–MS in Urine* and Feces After RSV Intake (n = 195) and (or) Fecal Cultures After Individual Incubation of RSV, DHRSV, LUNU, PINO, DHP, DHST, and 4HST (n = 12)a.

N° compound RT (min) mass target ion LOD; LOQ (nM) occurrence urine (μg/mg creatinine)b feces (μg/g)b
silylated
1 DHP 28.0 267 267 200; 500 ND    
2 4HST 28.1 268 268 200; 500 ND    
3 LUNU 29.3 358 179 50; 100 U, F, FC 88.2 ± 121.2 32.5 ± 28.7
4 PINO 31.3 356 356 100; 250 ND    
5 cis-RSV 32.0 444 444   U 274.0 ± 145.1c  
6 DHRSV 32.4 446 179 100; 250 U, F, FC 915.3 ± 654.8 34.1 ± 51.5
7 DHST 32.9 356 356 200; 500 U, F 11.2 ± 5.1 D
8 RSV 38.2 444 444 100; 250 U, F, FC 472.5 ± 269.0 1.4 ± 2.8
non-silylated
1′ 3HDB 21.8 198d 107 200; 500 ND    
2′ 4HDB 22.1 198d 107 100; 250 U, FC 13.2 ± 30.5  
a

U, urine; F, feces; FC, fecal culture; ND, not detected; D, detected but not quantified. *Hydrolyzed samples. 4HST, 4-hydroxy-trans-stilbene; LUNU, lunularin; DHRSV, dihydroresveratrol; DHST, 3,4′-dihydroxy-trans-stilbene; RSV (trans-resveratrol); 3HDB, 3-hydroxydibenzyl; 4HDB, 4-hydroxydibenzyl.

b

Mean ± SD.

c

Tentatively quantified as RSV.

d

Mass without silylation.